Press Release Source: Immunomedics, Inc. On Friday January 21, 2011, 10:00 am EST SAN FRANCISCO, Jan. 21, 2011 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU – News), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles [...]